Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?'
Licensing
Novocure (NVCR) stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment, Optune. Optune is a patch applied directly to the skin that uses electrical fields to disrupt the division of tumor cells. During the second quarter, Novocure notched $183.6 million in sales. Revenue popped 16% year over year and topped expectations for $172.4 million,…
